06:15 AM EDT, 10/16/2025 (MT Newswires) -- Sophia Genetics ( SOPH ) said Thursday it launched Sophia DDM Digital Twins, a research tool that builds virtual replicas of individual cancer patients to simulate treatment responses and outcomes for clinicians.

The system uses clinical, biological, imaging, and genomic data to model disease possibilities and test therapy strategies before real-life treatment begins.

The product is available on the Sophia DDM platform for lung cancer at launch, with additional cancer types to follow, the company said.

Sophia Genetics ( SOPH ) shares were up 9.3% in recent premarket activity.